Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Melanoma 1Esophageal Neoplasms 1

Interventions

pembrolizumab 62Nivolumab 40Ipilimumab 24trametinib 13dabrafenib 10Specimen Handling 10Magnetic Resonance Spectroscopy 10binimetinib 9Cyclophosphamide 8CTLA-4 Antigen 8Biopsy 8encorafenib 7fludarabine 6Radiosurgery 6Cisplatin 6relatlimab 5cemiplimab 5atezolizumab 5Pemetrexed 5Introns 5Interleukin-2 5tislelizumab 4lenvatinib 4fludarabine phosphate 4durvalumab 4dostarlimab 4cobimetinib 4avelumab 4Radiotherapy 4Paclitaxel 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Melanoma × sarcolipin × Clear all
NCT03757689 2025-02-11

Neoadjuvant PD-1 Blockade in Patients with Stage IIB/C Melanoma

Abramson Cancer Center at Penn Medicine

Phase 2 Active not recruiting
63 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡